NCT06288360: Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
- State
- Under way
- Phase
- Phase 2
- People
- 40 planned
- Started
- 12 Sep 2024
- Primary completion
- 31 Dec 2025
- Arms
- Neoadjuvant chemotherapy plus camrelizumab (NACI)
- Results
- None posted
- 1 Mar 2024: Trial registered
- 12 Sep 2024: Trial started